At the recent AAPS National Biotech Conference 2025, pharmaphorum editor-in-chief Jonah Comstock caught up with Dr Dhaval Shah, a professor of pharmaceutical sciences at the University of Buffalo and ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

The infant was born with a metabolic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which the ...

Health tech firm Datavant has reached an agreement to acquire Aetion, a specialist in real-world evidence (RWE), pooling ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

Changes to Health Technology Assessment (HTA) in Europe offer new opportunities to streamline processes and get innovative ...